Advances in the management of pancreatic cancer
- PMID: 38164628
- DOI: 10.1136/bmj-2022-073995
Advances in the management of pancreatic cancer
Abstract
Pancreatic cancer remains among the malignancies with the worst outcomes. Survival has been improving, but at a slower rate than other cancers. Multimodal treatment, including chemotherapy, surgical resection, and radiotherapy, has been under investigation for many years. Because of the anatomical characteristics of the pancreas, more emphasis on treatment selection has been placed on local extension into major vessels. Recently, the development of more effective treatment regimens has opened up new treatment strategies, but urgent research questions have also become apparent. This review outlines the current management of pancreatic cancer, and the recent advances in its treatment. The review discusses future treatment pathways aimed at integrating novel findings of translational and clinical research.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Conflict of interest statement
Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: MDC receives grants from Haemonetics, and is the primary investigator of a Boston Scientific sponsored study. TS does not have conflicts of interest to declare. SDK receives investigator initiated clinical trial funding from Genentech and AstraZeneca. She also receives preclinical research support from Roche and Amgen. WAM receives institutional clinical trial funding from Genentech, Beigene, Pfizer, NGM, Gossamer, ALX, Exelixis, EDDC/D3, Mirati, RasCal Therapeutics, and CanBAS. He is also a Data and Safety Monitoring Board member of QED, Amgen, and Zymeworks.
Similar articles
-
Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.Gan To Kagaku Ryoho. 1999 Jan;26(1):10-40. Gan To Kagaku Ryoho. 1999. PMID: 9987495 Review.
-
Role of surgery in pancreatic cancer.World J Gastroenterol. 2017 Jun 7;23(21):3765-3770. doi: 10.3748/wjg.v23.i21.3765. World J Gastroenterol. 2017. PMID: 28638216 Free PMC article.
-
The role of neoadjuvant therapy in pancreatic cancer: a review.Future Oncol. 2016 Mar;12(5):669-85. doi: 10.2217/fon.15.335. Epub 2016 Feb 1. Future Oncol. 2016. PMID: 26880384 Free PMC article. Review.
-
Combined-modality therapy in pancreatic cancer: current status and future directions.Cancer J. 2001 Jul-Aug;7(4):338-48. Cancer J. 2001. PMID: 11561609 Review.
-
Adjuvant therapy for pancreatic cancer: current status and future directions.Surg Oncol Clin N Am. 2004 Oct;13(4):737-49, xi. doi: 10.1016/j.soc.2004.06.010. Surg Oncol Clin N Am. 2004. PMID: 15350945 Review.
Cited by
-
Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective.Cost Eff Resour Alloc. 2024 Sep 18;22(1):70. doi: 10.1186/s12962-024-00578-5. Cost Eff Resour Alloc. 2024. PMID: 39294689 Free PMC article.
-
Normal tissue complication probability model for severe radiation-induced lymphopenia in patients with pancreatic cancer treated with concurrent chemoradiotherapy.Phys Imaging Radiat Oncol. 2024 Dec 22;33:100690. doi: 10.1016/j.phro.2024.100690. eCollection 2025 Jan. Phys Imaging Radiat Oncol. 2024. PMID: 39817285 Free PMC article.
-
Genetically predicted causal link between the plasma lipidome and pancreatic diseases: a bidirectional Mendelian randomization study.Front Nutr. 2025 Jan 15;11:1466509. doi: 10.3389/fnut.2024.1466509. eCollection 2024. Front Nutr. 2025. PMID: 39882037 Free PMC article.
-
Sciellin inhibits senescence and promotes pancreatic cancer progress by activating the notch signaling pathway.Sci Rep. 2025 May 8;15(1):16133. doi: 10.1038/s41598-025-88265-0. Sci Rep. 2025. PMID: 40341648 Free PMC article.
-
Identification of M2 macrophage-related genes for establishing a prognostic model in pancreatic cancer: FCGR3A as key gene.Oncol Res. 2024 Nov 13;32(12):1851-1866. doi: 10.32604/or.2024.055286. eCollection 2024. Oncol Res. 2024. PMID: 39574475 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical